Novacyt S.A.

Q: What was Novacyt S.A.’s price range in the past 12 months?

Novacyt S.A. lowest stock price was €0.42 and its highest was €0.84 in the past 12 months.

Q: What is Novacyt S.A.’s market cap?

Novacyt S.A.’s market cap is €32.59M.

Q: When is Novacyt S.A.’s upcoming earnings report date?

Novacyt S.A.’s upcoming earnings report date is Apr 23, 2026 which is in 174 days.

Q: How were Novacyt S.A.’s earnings last quarter?

Novacyt S.A. released its earnings results on Sep 30, 2025. The company reported -€0.107 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.107.

Q: Is Novacyt S.A. overvalued?

According to Wall Street analysts Novacyt S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Novacyt S.A. pay dividends?

Novacyt S.A. does not currently pay dividends.

Q: What is Novacyt S.A.’s EPS estimate?

Novacyt S.A.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Novacyt S.A. have?

Novacyt S.A. has 70,626,250 shares outstanding.

Q: What happened to Novacyt S.A.’s price movement after its last earnings report?

Novacyt S.A. reported an EPS of -€0.107 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.24%.

Q: Which hedge fund is a major shareholder of Novacyt S.A.?

Currently, no hedge funds are holding shares in FR:ALNOV

Compare

11 Followers

ALNOV Stock Chart & Stats

€0.46

<€0.01(0.56%)

At close: Jan 09 4:00 PM EST

€0.46

<€0.01(0.56%)

Day’s Range― - ―

52-Week Range€0.42 - €0.84

Previous CloseN/A

Volume192.22K

Average Volume (3M)194.37K

Market Cap

€32.59M

Enterprise Value€19.73M

Total Cash (Recent Filing)€44.06M

Total Debt (Recent Filing)€13.70M

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding70,626,250

10 Day Avg. Volume221,371

30 Day Avg. Volume194,367

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Novacyt News

Novacyt Unveils Growth Strategy and FY25 Outlook

Novacyt ( ($FR:ALNOV) ) has provided an announcement. Novacyt S.A. has announced a strategy update and an investor...

9d ago

Novacyt Provides Update on Liquidity Agreement and Voting Rights

Novacyt ( ($FR:ALNOV) ) just unveiled an announcement. Novacyt announced its monthly update on the Liquidity Agreement with...

29d ago

Novacyt S.A. Reports Stable Revenue Amid Strategic Growth

Novacyt S.A. ( ($NVYTF) ) has released its Q2 earnings. Here is a breakdown of the information Novacyt...

30d ago

Novacyt Reports Steady Growth and Strategic Advancements in H1 2025

Novacyt ( ($FR:ALNOV) ) has provided an announcement. Novacyt S.A. reported its unaudited interim results for the first...

1M ago

Novacyt Reports Steady Growth and Strategic Advancements in H1 2025

Novacyt ( ($FR:ALNOV) ) just unveiled an update. Novacyt S.A. reported its unaudited interim results for the first...

1M ago

Novacyt to Announce Interim Results for H1 2025

Novacyt ( ($FR:ALNOV) ) has shared an announcement. Novacyt S.A. announced it will release its unaudited interim results...

1M ago

Novacyt Appoints Singer Capital Markets as Joint Corporate Broker

Novacyt ( ($FR:ALNOV) ) has issued an announcement. Novacyt S.A. has announced the appointment of Singer Capital Markets...

2M ago

Novacyt Concludes Legal Proceedings with Lab 21 Subsidiary

Novacyt ( ($FR:ALNOV) ) has issued an update. Novacyt S.A. announced the conclusion of legal proceedings involving its...

2M ago

Novacyt Updates on Liquidity Agreement and Share Trading

The latest update is out from Novacyt ( ($FR:ALNOV) ). Novacyt S.A. has provided an update on its...

2M ago

Novacyt Updates on Liquidity Agreement and Voting Rights

Novacyt ( ($FR:ALNOV) ) just unveiled an announcement. Novacyt S.A. has provided an update on its liquidity agreement...

3M ago

ALNOV FAQ

What was Novacyt S.A.’s price range in the past 12 months?

Novacyt S.A. lowest stock price was €0.42 and its highest was €0.84 in the past 12 months.

What is Novacyt S.A.’s market cap?

Novacyt S.A.’s market cap is €32.59M.

When is Novacyt S.A.’s upcoming earnings report date?

Novacyt S.A.’s upcoming earnings report date is Apr 23, 2026 which is in 174 days.

How were Novacyt S.A.’s earnings last quarter?

Novacyt S.A. released its earnings results on Sep 30, 2025. The company reported -€0.107 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.107.

Is Novacyt S.A. overvalued?

According to Wall Street analysts Novacyt S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Novacyt S.A. pay dividends?

Novacyt S.A. does not currently pay dividends.

What is Novacyt S.A.’s EPS estimate?

Novacyt S.A.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Novacyt S.A. have?

Novacyt S.A. has 70,626,250 shares outstanding.

What happened to Novacyt S.A.’s price movement after its last earnings report?

Novacyt S.A. reported an EPS of -€0.107 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.24%.

Which hedge fund is a major shareholder of Novacyt S.A.?

Currently, no hedge funds are holding shares in FR:ALNOV

Company Description

Novacyt S.A.

Novacyt S.A. is a global diagnostics company specializing in the development, manufacturing, and commercialization of innovative diagnostic tests and products, primarily in the fields of infectious diseases, oncology, and other medical conditions. The company operates in various sectors, including molecular diagnostics and immunodiagnostics, offering a range of products that leverage advanced technologies to provide rapid and accurate results. Novacyt's core product offerings include PCR tests for the detection of viral infections, including COVID-19, as well as other diagnostic solutions that cater to both clinical and research applications.